Cargando…

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS

INTRODUCTION: This pre-specified subgroup analysis evaluated the efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) triple therapy versus corresponding dual therapies in the China subgroup of the phase III, double-blind KRONOS study in patients with m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chen, Yang, Ting, Kang, Jian, Chen, Rongchang, Zhao, Li, He, Huijie, Assam, Pryseley N., Su, Rong, Bourne, Eric, Ballal, Shaila, DeAngelis, Kiernan, Dorinsky, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140742/
https://www.ncbi.nlm.nih.gov/pubmed/32152869
http://dx.doi.org/10.1007/s12325-020-01266-5
_version_ 1783519060254785536
author Wang, Chen
Yang, Ting
Kang, Jian
Chen, Rongchang
Zhao, Li
He, Huijie
Assam, Pryseley N.
Su, Rong
Bourne, Eric
Ballal, Shaila
DeAngelis, Kiernan
Dorinsky, Paul
author_facet Wang, Chen
Yang, Ting
Kang, Jian
Chen, Rongchang
Zhao, Li
He, Huijie
Assam, Pryseley N.
Su, Rong
Bourne, Eric
Ballal, Shaila
DeAngelis, Kiernan
Dorinsky, Paul
author_sort Wang, Chen
collection PubMed
description INTRODUCTION: This pre-specified subgroup analysis evaluated the efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) triple therapy versus corresponding dual therapies in the China subgroup of the phase III, double-blind KRONOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). METHODS: Patients were randomized 2:2:1:1 to BGF MDI 320/18/9.6 μg, glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg, budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg, or budesonide/formoterol fumarate dry powder inhaler (BUD/FORM DPI) 400/12 μg twice daily for 24 weeks. The primary endpoint was change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV(1)) over weeks 12–24. Secondary endpoints included symptoms, health-related quality of life, and safety. Rate of moderate/severe COPD exacerbations was an additional efficacy endpoint. RESULTS: In the China subgroup (n = 432; 22.7% of the KRONOS population), BGF MDI demonstrated nominally significant improvements in the primary endpoint versus BFF MDI (least squares mean (LSM) difference 68 mL; P = 0.0035) and BUD/FORM DPI (LSM difference 78 mL; P = 0.0010) but not GFF MDI (LSM difference − 4 mL; P = 0.8316). BGF MDI demonstrated at least numerical improvements versus comparators in secondary lung function and symptom endpoints. BGF MDI reduced the rate of moderate/severe COPD exacerbations versus GFF MDI (rate ratio 0.41; P = 0.0030), with numerical benefits versus BFF MDI and BUD/FORM DPI. All treatments were well tolerated. CONCLUSIONS: Results demonstrated that BGF MDI showed benefits on lung function (vs inhaled corticosteroid/long-acting β(2)-agonist), as well as symptoms and exacerbations relative to dual therapies. Findings support BGF MDI use in Chinese patients with moderate to very severe COPD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT02497001. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01266-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7140742
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-71407422020-04-14 Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS Wang, Chen Yang, Ting Kang, Jian Chen, Rongchang Zhao, Li He, Huijie Assam, Pryseley N. Su, Rong Bourne, Eric Ballal, Shaila DeAngelis, Kiernan Dorinsky, Paul Adv Ther Original Research INTRODUCTION: This pre-specified subgroup analysis evaluated the efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) triple therapy versus corresponding dual therapies in the China subgroup of the phase III, double-blind KRONOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). METHODS: Patients were randomized 2:2:1:1 to BGF MDI 320/18/9.6 μg, glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg, budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg, or budesonide/formoterol fumarate dry powder inhaler (BUD/FORM DPI) 400/12 μg twice daily for 24 weeks. The primary endpoint was change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV(1)) over weeks 12–24. Secondary endpoints included symptoms, health-related quality of life, and safety. Rate of moderate/severe COPD exacerbations was an additional efficacy endpoint. RESULTS: In the China subgroup (n = 432; 22.7% of the KRONOS population), BGF MDI demonstrated nominally significant improvements in the primary endpoint versus BFF MDI (least squares mean (LSM) difference 68 mL; P = 0.0035) and BUD/FORM DPI (LSM difference 78 mL; P = 0.0010) but not GFF MDI (LSM difference − 4 mL; P = 0.8316). BGF MDI demonstrated at least numerical improvements versus comparators in secondary lung function and symptom endpoints. BGF MDI reduced the rate of moderate/severe COPD exacerbations versus GFF MDI (rate ratio 0.41; P = 0.0030), with numerical benefits versus BFF MDI and BUD/FORM DPI. All treatments were well tolerated. CONCLUSIONS: Results demonstrated that BGF MDI showed benefits on lung function (vs inhaled corticosteroid/long-acting β(2)-agonist), as well as symptoms and exacerbations relative to dual therapies. Findings support BGF MDI use in Chinese patients with moderate to very severe COPD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT02497001. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01266-5) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-03-06 2020 /pmc/articles/PMC7140742/ /pubmed/32152869 http://dx.doi.org/10.1007/s12325-020-01266-5 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Wang, Chen
Yang, Ting
Kang, Jian
Chen, Rongchang
Zhao, Li
He, Huijie
Assam, Pryseley N.
Su, Rong
Bourne, Eric
Ballal, Shaila
DeAngelis, Kiernan
Dorinsky, Paul
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
title Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
title_full Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
title_fullStr Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
title_full_unstemmed Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
title_short Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
title_sort efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in chinese patients with copd: a subgroup analysis of kronos
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140742/
https://www.ncbi.nlm.nih.gov/pubmed/32152869
http://dx.doi.org/10.1007/s12325-020-01266-5
work_keys_str_mv AT wangchen efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT yangting efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT kangjian efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT chenrongchang efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT zhaoli efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT hehuijie efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT assampryseleyn efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT surong efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT bourneeric efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT ballalshaila efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT deangeliskiernan efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos
AT dorinskypaul efficacyandsafetyofbudesonideglycopyrrolateformoterolfumaratemetereddoseinhalerinchinesepatientswithcopdasubgroupanalysisofkronos